http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-122019016866-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60f67cf07e3fdc9c7d98b1c36039ec12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate | 2010-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29d5690058ecea043df1039ac8e2d578 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f94936277efc4261407d8cad5101c3e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d256291f0abd0d1f345860b6b7ae4ad6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2423d7dbaea1ae85332c7455270aa7bd |
| publicationDate | 2021-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-122019016866-B1 |
| titleOfInvention | METHOD FOR ASSESSING (ANALYZING) THE RISK OF POTENTIAL ADVERSE EFFECTS FOR A HUMAN PATIENT MEDIATED BY THE ADMINISTRATION OF A SPECIFIC ANTIBODYBODY OF CD19XCD3 |
| abstract | use of bispecific cd19xcd3 antibody in the treatment of malignant cd19-positive lymphocytes in a human patient having a b: t cell ratio of about 1: 5 or less. the present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by administering a bispecific cd19xcd3 antibody to said patient comprising determining the ratio of b cells to t cells of said patient, wherein a ratio of about 1: 5 or less is indicative of a risk of potential adverse effects for said patient. therefore, the present invention relates to a method (dosage regimen) for administering a bispecific cd19xcd3 antibody to a human patient having a b: t cell ratio of about 1: 5 or less, comprising (a) administering a first dose of said antibody over a first period of time; and consecutively (b) administering a second dose of said antibody over a second period of time, wherein said second dose exceeds said first dose. a pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods / dosage regimen of the present invention is also disclosed. |
| priorityDate | 2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.